CL2024002860A1 - Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso - Google Patents

Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso

Info

Publication number
CL2024002860A1
CL2024002860A1 CL2024002860A CL2024002860A CL2024002860A1 CL 2024002860 A1 CL2024002860 A1 CL 2024002860A1 CL 2024002860 A CL2024002860 A CL 2024002860A CL 2024002860 A CL2024002860 A CL 2024002860A CL 2024002860 A1 CL2024002860 A1 CL 2024002860A1
Authority
CL
Chile
Prior art keywords
antibody
drug conjugates
receptor alpha
folate receptor
methods
Prior art date
Application number
CL2024002860A
Other languages
English (en)
Spanish (es)
Inventor
R Rich James
Daniel Barnscher Stuart
Edmund Petersen Mark
Colombo Raffaele
G Brant Michael
Michel Auguste Lasalle Manuel
H Davies Rupert
Urosev Dunja
Singh Kang Sukhbir
Wing Yiu Chan Peter
Das Samir
Hernandez Rojas Andrea
William Gene Robert
G H Young Ada
Oliver Lawn Samuel
Chui Danny
Browman Duncan
Clavette Brandon
Original Assignee
Zymeworks Bc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Bc Inc filed Critical Zymeworks Bc Inc
Publication of CL2024002860A1 publication Critical patent/CL2024002860A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024002860A 2022-03-25 2024-09-25 Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso CL2024002860A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263324003P 2022-03-25 2022-03-25
US202263417250P 2022-10-18 2022-10-18
US202363450607P 2023-03-07 2023-03-07

Publications (1)

Publication Number Publication Date
CL2024002860A1 true CL2024002860A1 (es) 2025-02-21

Family

ID=88099491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002860A CL2024002860A1 (es) 2022-03-25 2024-09-25 Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso

Country Status (11)

Country Link
US (2) US12433952B2 (enExample)
EP (1) EP4499698A1 (enExample)
JP (1) JP7877480B2 (enExample)
KR (1) KR20240162575A (enExample)
AU (1) AU2023239448A1 (enExample)
CA (1) CA3245602A1 (enExample)
CL (1) CL2024002860A1 (enExample)
CO (1) CO2024012877A2 (enExample)
IL (1) IL315393A (enExample)
MX (1) MX2024011775A (enExample)
WO (1) WO2023178452A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
EP4688787A1 (en) * 2023-04-07 2026-02-11 Innovent Biologics (Suzhou) Co., Ltd. Antibody-drug conjugates of camptothecin derivatives and uses thereof
AU2024302681A1 (en) * 2023-06-13 2026-01-15 Chengdu Brilliant Pharmaceutical Co., Ltd. Camptothecin derivative for treating or preventing cancer, and antibody-drug conjugate thereof
CN122122183A (zh) * 2023-10-19 2026-05-29 酵活英属哥伦比亚有限公司 抗napi2b抗体-药物缀合物和使用方法
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025235686A1 (en) * 2024-05-07 2025-11-13 Aarvik Therapeutics, Inc. Fluorocamptothecin compounds, conjugates, and methods thereof
CN118791615B (zh) * 2024-07-22 2025-03-21 上海生物制品研究所有限责任公司 抗FRα抗体或抗原结合片段、抗体偶联药物及其应用
WO2026057740A1 (en) * 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
JP2002255821A (ja) 2001-03-06 2002-09-11 Yakult Honsha Co Ltd 抗癌剤耐性癌に対する治療剤
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
CN111936169A (zh) 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
RS64961B1 (sr) 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
CN110128501A (zh) 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
CA3144784A1 (en) 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
KR20230026983A (ko) 2020-05-11 2023-02-27 후닐라이프 바이오테크놀로지, 인코포레이트 알파-엔올라아제 항체들을 포함하는 약물 접합체 및 그의 이용
PH12022500032A1 (en) 2020-06-19 2024-02-26 Hangzhou Dac Biotech Co Ltd Conjugates of a cell-binding molecule with camptothecin analogs
CN114569735A (zh) 2020-12-01 2022-06-03 泰州复旦张江药业有限公司 一种连接基-药物偶联物、制备方法及应用
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
KR20240031235A (ko) * 2021-05-27 2024-03-07 자임워크스 비씨 인코포레이티드 캄프토테신 유사체, 접합체 및 사용 방법
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4499697A4 (en) 2022-03-25 2026-03-18 Zymeworks Bc Inc Anti-alpha folate receptor antibodies and methods of use

Also Published As

Publication number Publication date
JP7877480B2 (ja) 2026-06-22
MX2024011775A (es) 2024-11-08
CA3245602A1 (en) 2023-09-28
US20250339552A1 (en) 2025-11-06
JP2025510791A (ja) 2025-04-15
WO2023178452A1 (en) 2023-09-28
CO2024012877A2 (es) 2024-10-10
EP4499698A1 (en) 2025-02-05
US20240424125A1 (en) 2024-12-26
KR20240162575A (ko) 2024-11-15
AU2023239448A1 (en) 2024-11-07
IL315393A (en) 2024-11-01
US12433952B2 (en) 2025-10-07

Similar Documents

Publication Publication Date Title
CO2024012877A2 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
MX2023013738A (es) Analogos de la camptotecina, conjugados y metodos de uso.
CO2025004508A2 (es) Conjugados de anticuerpo-farmaco dirigidos a glipicano-3 y métodos de uso
CO2023004110A2 (es) Anticuerpos anti-fgfr2 y métodos para usarlos
BR112022017064A2 (pt) Derivados da camptotecina e seus conjugados
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX2018010562A (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
ECSP22007981A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
MX2024005702A (es) Derivado de imida fusionado.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
MX2025003695A (es) Conjugados de anticuerpo y farmaco que se dirigen a napi2b y metodos de uso
MX2023015471A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap).
CO2020003512A2 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CO2025004806A2 (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y usos de los mismos
MX2025005811A (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
AR134365A1 (es) CONJUGADOS ANTICUERPO-FÁRMACO QUE SE DIRIGEN A EGFR / c-MET Y MÉTODOS DE PREPARACIÓN Y USOS DE ESTOS
CL2023000021A1 (es) Fármacos enlazadores y conjugados de anticuerpo-fármaco antifolato.
CO2025002048A2 (es) Anticuerpos anti monometil auristatina y fragmentos de anticuerpos
MX2025007523A (es) Conjugados de anticuerpo-farmaco que eligen como blanco al receptor uparap que comprenden derivados de exatecan
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
CO2025004814A2 (es) Novedosos conjugados-anticuerpo-droga con novedosos anticuerpos napi2b, métodos terapéuticos y usos de los mismos
MX2021014729A (es) Metodos y composiciones para tratar enfermedades autoinmunitarias.